hypertension
Conditions
Interventions
irbesartan 100mg/day 7days irbesartan 200mg/day 20days a 4-week washout period candesartan 8mg/day 7days candesartan 12mg/day 20days a 4-week washout period valsartan 80mg/day 7days valsartan 1
Sponsors
Division of Clinical Pharmacology, Jichi Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with untreated hypertenstion OR Inadequately-controlled hypertensive patients treated with a Ca channel blocker for over 3 months Patients without any inadequately-controlled disease other than hypertension Patients who can give their written consent
Exclusion criteria
Exclusion criteria: Patients who have diabetes, chronic kidney disease, cardiovascular disease, or 3 or more following risk factors: current smoking, inadequately-controlled dyslipidemia, obesity, metabolic syndrome, and early family history of cardiovascular disease. Patients treated with any antihypertensive medication other than Ca channel blocker Patients with moderate or severe liver injury Patients with anemia Patients who are or might become pregnant Patients treated with a medication which is known to affect CYP2C9 activity or glucuronyl transferase activiry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Associations between the characteristics of angiotensin II blockade and changes in the markers of pleiotropic effects | — |
Secondary
| Measure | Time frame |
|---|---|
| pressure-lowering effect pharmacokinetics | — |
Countries
Japan
Outcome results
None listed